842 related articles for article (PubMed ID: 22162288)
21. Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases.
Beyer V; Mühlematter D; Parlier V; Cabrol C; Bougeon-Mamin S; Solenthaler M; Tobler A; Pugin P; Gregor M; Hitz F; Hess U; Chapuis B; Laurencet F; Schanz U; Schmidt PM; van Melle G; Jotterand M
Cancer Genet Cytogenet; 2005 Jul; 160(2):97-119. PubMed ID: 15993266
[TBL] [Abstract][Full Text] [Related]
22. Molecular cytogenetic characterization of rearrangements involving 12p in leukemia.
Vieira L; Marques B; Cavaleiro C; Ambrósio AP; Jorge M; Neto A; Costa JM; Júnior EC; Boavida MG
Cancer Genet Cytogenet; 2005 Mar; 157(2):134-9. PubMed ID: 15721634
[TBL] [Abstract][Full Text] [Related]
23. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
[TBL] [Abstract][Full Text] [Related]
24. Deletion 15q as the sole abnormality in acute myeloid leukemia: report of three cases and review of the literature.
Lu G; Yin CC; Medeiros LJ; Abruzzo LV
Cancer Genet Cytogenet; 2009 Jan; 188(2):118-23. PubMed ID: 19100517
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndrome/acute myeloid leukemia with t(3;21)(q26.2;q22) is commonly a therapy-related disease associated with poor outcome.
Li S; Yin CC; Medeiros LJ; Bueso-Ramos C; Lu G; Lin P
Am J Clin Pathol; 2012 Jul; 138(1):146-52. PubMed ID: 22706870
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of ETV6-RUNX1 fusion gene in children with acute lymphoblastic leukemia in China.
Gao YJ; Zhu XH; Yang Y; Wu Y; Lu FJ; Zhai XW; Wang HS
Cancer Genet Cytogenet; 2007 Oct; 178(1):57-60. PubMed ID: 17889709
[TBL] [Abstract][Full Text] [Related]
27. ETV6/RUNX1 fusion at diagnosis and relapse: some prognostic indications.
Martineau M; Jalali GR; Barber KE; Broadfield ZJ; Cheung KL; Lilleyman J; Moorman AV; Richards S; Robinson HM; Ross F; Harrison CJ
Genes Chromosomes Cancer; 2005 May; 43(1):54-71. PubMed ID: 15704129
[TBL] [Abstract][Full Text] [Related]
28. Cytogenetic abnormalities in 532 patients with myeloid leukemias and myelodyplastic syndrome. The Czechoslovak MDS Cooperative Group.
Michalová K; Musilová J; Zemanová Z
Czech Med; 1990; 13(4):133-44. PubMed ID: 2081440
[TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic syndrome with inv(3)(q21q26.2) or t(3;3)(q21;q26.2) has a high risk for progression to acute myeloid leukemia.
Cui W; Sun J; Cotta CV; Medeiros LJ; Lin P
Am J Clin Pathol; 2011 Aug; 136(2):282-8. PubMed ID: 21757602
[TBL] [Abstract][Full Text] [Related]
30. Analysis of complex chromosomal rearrangements in adult patients with MDS and AML by multicolor FISH.
Babicka L; Ransdorfova S; Brezinova J; Zemanova Z; Sindelarova L; Siskova M; Maaloufova J; Cermak J; Michalova K
Leuk Res; 2007 Jan; 31(1):39-47. PubMed ID: 16687173
[TBL] [Abstract][Full Text] [Related]
31. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
32. Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.
Larsson N; Lilljebjörn H; Lassen C; Johansson B; Fioretos T
Eur J Haematol; 2012 Feb; 88(2):136-43. PubMed ID: 21933280
[TBL] [Abstract][Full Text] [Related]
33. Transformation of myelodysplastic syndromes into acute myeloid leukemias.
Shi J; Shao ZH; Liu H; Bai J; Cao YR; He GS; Tu MF; Wang XL; Hao YS; Yang TY; Yang CL
Chin Med J (Engl); 2004 Jul; 117(7):963-7. PubMed ID: 15265365
[TBL] [Abstract][Full Text] [Related]
34. Hyperactivation of the RAS signaling pathway in myelodysplastic syndrome with AML1/RUNX1 point mutations.
Niimi H; Harada H; Harada Y; Ding Y; Imagawa J; Inaba T; Kyo T; Kimura A
Leukemia; 2006 Apr; 20(4):635-44. PubMed ID: 16467864
[TBL] [Abstract][Full Text] [Related]
35. Next-generation sequencing and molecular cytogenetic characterization of ETV6-LYN fusion due to chromosomes 1, 8 and 12 rearrangement in acute myeloid leukemia.
Ma ESK; Wan TSK; Au CH; Ho DN; Ma SY; Ng MHL; Chan TL
Cancer Genet; 2017 Dec; 218-219():15-19. PubMed ID: 29153093
[TBL] [Abstract][Full Text] [Related]
36. MDS/AML-associated cytogenetic abnormalities in multiple myeloma and monoclonal gammopathy of undetermined significance: evidence for frequent de novo occurrence and multipotent stem cell involvement of del(20q).
Nilsson T; Nilsson L; Lenhoff S; Rylander L; Astrand-Grundström I; Strömbeck B; Höglund M; Turesson I; Westin J; Mitelman F; Jacobsen SE; Johansson B
Genes Chromosomes Cancer; 2004 Nov; 41(3):223-31. PubMed ID: 15334545
[TBL] [Abstract][Full Text] [Related]
37. ETV6 mutations and loss in AML-M0.
Silva FP; Morolli B; Storlazzi CT; Zagaria A; Impera L; Klein B; Vrieling H; Kluin-Nelemans HC; Giphart-Gassler M
Leukemia; 2008 Aug; 22(8):1639-43. PubMed ID: 18305557
[No Abstract] [Full Text] [Related]
38. RUNX1 aberrations in ETV6/RUNX1-positive and ETV6/RUNX1-negative patients: its hemato-pathological and prognostic significance in a large cohort (619 cases) of ALL.
Pais AP; Amare Kadam PS; Raje GC; Banavali S; Parikh P; Kurkure P; Arora B; Gujral S; Kumar SA; Badrinath Y
Pediatr Hematol Oncol; 2008 Sep; 25(6):582-97. PubMed ID: 18728978
[TBL] [Abstract][Full Text] [Related]
39. Somatic heterozygous mutations in ETV6 (TEL) and frequent absence of ETV6 protein in acute myeloid leukemia.
Barjesteh van Waalwijk van Doorn-Khosrovani S; Spensberger D; de Knegt Y; Tang M; Löwenberg B; Delwel R
Oncogene; 2005 Jun; 24(25):4129-37. PubMed ID: 15806161
[TBL] [Abstract][Full Text] [Related]
40. Myeloid malignancies with translocation t(4;12)(q11-13;p13): molecular landscape, clonal hierarchy and clinical outcomes.
Parinet V; Chapiro E; Bidet A; Gaillard B; Maarek O; Simon L; Lefebvre C; Defasque S; Mozziconacci MJ; Quinquenel A; Decamp M; Lifermann F; Ali-Ammar N; Maillon A; Baron M; Martin M; Struski S; Penther D; Micol JB; Auger N; Bilhou-Nabera C; Martignoles JA; Tondeur S; Nguyen-Khac F; Hirsch P; Roos-Weil D;
J Cell Mol Med; 2021 Oct; 25(20):9557-9566. PubMed ID: 34492730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
